keyword
MENU ▼
Read by QxMD icon Read
search

Lisdexamfetamine

keyword
https://www.readbyqxmd.com/read/28936175/pharmacokinetics-and-pharmacodynamics-of-lisdexamfetamine-compared-with-d-amphetamine-in-healthy-subjects
#1
Patrick C Dolder, Petra Strajhar, Patrick Vizeli, Felix Hammann, Alex Odermatt, Matthias E Liechti
Rationale: Lisdexamfetamine is a prodrug of D-amphetamine used for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is thought to have a prolonged pharmacokinetic profile compared with oral D-amphetamine, possibly associated with lower drug liking and a lower risk of oral misuse. However, differences in the pharmacokinetics and pharmacodynamics of lisdexamfetamine and D-amphetamine have not been directly compared. Methods: Equimolar doses of D-amphetamine (40 mg) and lisdexamfetamine (100 mg), and placebo were administered in 24 healthy subjects in a randomized, double-blind, placebo-controlled, cross-over study...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28933969/psychopharmacological-advances-in-eating-disorders
#2
Hubertus Himmerich, Janet Treasure
Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) are the primary eating disorders (EDs). The only psychopharmacological treatment options for EDs with approval in some countries include fluoxetine for BN and lisdexamfetamine for BED. Given the high comorbidity and genetic correlations with other psychiatric disorders, it seems possible that novel medications for these conditions might also be effective in EDs. Areas Covered: The current scientific literature has increased our understanding of how medication could be beneficial for patients with EDs on a molecular, functional and behavioral level...
September 21, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28857719/a-randomized-double-blind-placebo-controlled-dose-ranging-study-of-lisdexamfetamine-dimesylate-augmentation-for-major-depressive-disorder-in-adults-with-inadequate-response-to-antidepressant-therapy
#3
Cynthia Richards, Dan V Iosifescu, Rajnish Mago, Elias Sarkis, James Reynolds, Brooke Geibel, Matthew Dauphin
BACKGROUND: This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy. METHODS: Eligible adults (18-65 years) were assigned to antidepressant monotherapy (escitalopram or venlafaxine extended-release) plus lisdexamfetamine dimesylate-matching placebo during an eight-week single-blind lead-in phase...
August 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28855799/review-of-lisdexamfetamine-dimesylate-in-adults-with-attention-deficit-hyperactivity-disorder
#4
REVIEW
Jadwiga Najib, Dexter Wimer, Julie Zeng, Kristina W Lam, Natalya Romanyak, Eva Paige Morgan, Anu Thadavila
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity disorder (ADHD) dosed once daily. Due to its long-acting properties, LDX remains pharmacologically inactive until an enzymatic process predominantly associated with red blood cells converts it to the active ingredient, d-amphetamine and the amino acid lysine. The efficacy of LDX over placebo has been demonstrated in several studies in adults with moderate to severe ADHD with significant improvements noted in ADHD rating scales, Clinical Global Improvement scores, and assessments of executive function, for all doses of LDX (30-70 mg daily)...
2017: Journal of Central Nervous System Disease
https://www.readbyqxmd.com/read/28837827/pharmacotherapy-of-emotional-dysregulation-in-adults-with-adhd-a-systematic-review-and-meta-analysis
#5
REVIEW
Francesca Lenzi, Samuele Cortese, Joseph Harris, Gabriele Masi
Emotional dysregulation (ED) is a dysfunction in modifying an emotional state in an adaptive and goal oriented way, with excitability, ease anger, and mood lability. It is present in up to 70% of adults with ADHD, regardless of other comorbidities, and substantially worsens the psychosocial outcomes of the disorder. Besides fronto-parietal circuits mediating top-down control, brain regions involved in bottom-up processes (e.g., amygdala, orbitofrontal cortex, and ventral striatum) are implicated in ED. We performed a systematic review/meta-analysis of double-blind randomized controlled trials of ADHD medications to assess their effects on ED in adults with ADHD...
August 25, 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/28836895/correlations-between-clinical-trial-outcomes-based-on-symptoms-functional-impairments-and-quality-of-life-in-children-and-adolescents-with-adhd
#6
David R Coghill, Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss, Michael Huss
OBJECTIVE: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD. METHOD: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference)...
August 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28806268/pharmacotherapy-of-eating-disorders
#7
Haley Davis, Evelyn Attia
PURPOSE OF REVIEW: Medications are commonly prescribed in the treatment of eating disorders. In this review, we discuss relevant medications used for the treatment of bulimia nervosa, binge eating disorder (BED), and anorexia nervosa. We focus on recent research developments, where applicable, in addition to discussing important findings from older studies to provide a complete synopsis of the current evidence base for eating disorder treatment using pharmacologic agents. RECENT FINDINGS: Medications are generally useful for patients with bulimia nervosa and BED...
August 12, 2017: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/28700805/efficacy-of-lisdexamfetamine-in-adults-with-moderate-to-severe-binge-eating-disorder-a-randomized-clinical-trial
#8
James I Hudson, Susan L McElroy, M Celeste Ferreira-Cornwell, Jana Radewonuk, Maria Gasior
Importance: The ability of pharmacotherapies to prevent relapse and maintain efficacy with long-term treatment in psychiatric conditions is important. Objective: To assess lisdexamfetamine dimesylate maintenance of efficacy in adults with moderate to severe binge-eating disorder. Design, Setting, and Participants: A multinational, phase 3, double-blind, placebo-controlled, randomized withdrawal study including 418 participants was conducted at 49 clinical research study sites from January 27, 2014, to April 8, 2015...
September 1, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28667569/long-term-safety-and-efficacy-of-lisdexamfetamine-dimesylate-in-children-and-adolescents-with-adhd-a-phase-iv-2-year-open-label-study-in-europe
#9
David R Coghill, Tobias Banaschewski, Peter Nagy, Isabel Hernández Otero, César Soutullo, Brian Yan, Beatriz Caballero, Alessandro Zuddas
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is increasingly recognized as a persistent disorder requiring long-term management. OBJECTIVES: Our objective was to evaluate the 2-year safety and efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with ADHD. METHODS: Participants (aged 6-17 years) with ADHD received open-label, dose-optimized LDX 30, 50, or 70 mg/day for 104 weeks. Safety monitoring included treatment-emergent adverse events (TEAEs), vital signs, electrocardiography, and growth...
July 2017: CNS Drugs
https://www.readbyqxmd.com/read/28651185/treatment-of-neurocognitive-symptoms-in-unipolar-depression-a-systematic-review-and-future-perspectives
#10
REVIEW
E Salagre, B Solé, Y Tomioka, B S Fernandes, D Hidalgo-Mazzei, M Garriga, E Jimenez, J Sanchez-Moreno, E Vieta, I Grande
BACKGROUND: Cognitive symptoms in Major Depressive Disorder (MDD) are persistent and commonly entail neurocognitive impairment and a decline in quality of life. This systematic review gathers the current scientific evidence on therapeutic strategies for neuropsychological impairment in MDD. METHOD: A systematic search on PubMed, PsycINFO and Clinicaltrials.gov was carried out on December 2016 according to PRISMA using Boolean terms to identify interventions for the treatment of cognitive dysfunction in MDD...
October 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28590365/the-efficacy-of-psychostimulants-in-major-depressive-episodes-a-systematic-review-and-meta-analysis
#11
Roger S McIntyre, Yena Lee, Aileen J Zhou, Joshua D Rosenblat, Evyn M Peters, Raymond W Lam, Sidney H Kennedy, Carola Rong, Jeanette M Jerrell
BACKGROUND: Psychostimulants are frequently prescribed off-label for adults with major depressive disorder or bipolar disorder. The frequent and increasing usage of stimulants in mood disorders warrants a careful appraisal of the efficacy of this class of agents. Herein, we aim to estimate the efficacy of psychostimulants in adults with unipolar or bipolar depression. METHODS: The PubMed/Medline database was searched from inception to January 16, 2016 for randomized, placebo-controlled clinical trials investigating the antidepressant efficacy of psychostimulants in the treatment of adults with unipolar or bipolar depression...
August 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28547702/emerging-treatments-in-eating-disorders
#12
REVIEW
Michael Lutter
Eating disorders (EDs), including anorexia nervosa, bulimia nervosa, and binge-eating disorder, constitute a class of common and deadly psychiatric disorders. While numerous studies in humans highlight the important role of neurobiological alterations in the development of ED-related behaviors, the precise neural substrate that mediates this risk is unknown. Historically, pharmacological interventions have played a limited role in the treatment of eating disorders, typically providing symptomatic relief of comorbid psychiatric issues, like depression and anxiety, in support of the standard nutritional and psychological treatments...
July 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28513760/cell-therapy-in-the-treatment-of-bipolar-mania-in-an-animal-model-a-proof-of-concept-study
#13
Bruna M Ascoli, Rafael Colombo, Luiza P Géa, Paula B Terraciano, Sabrina B Pizzato, Fernanda S de Oliveira, Elizabeth Cirne-Lima, Flávio Kapczinski, Adriane R Rosa
Introduction: The rationale of mesenchymal stem cells (MSCs) as a novel therapeutic approach in certain neurodegenerative diseases is based on their ability to promote neurogenesis. Hippocampal atrophy has been related to bipolar disorder (BD) in preclinical, imaging and postmortem studies. Therefore, the development of new strategies to stimulate the neurogenesis process in BD is crucial. Objectives: To investigate the behavioral and neurochemical changes induced by transplantation of MSCs in a model of mania-like behavior induced by lisdexamfetamine dimesylate (LDX)...
May 15, 2017: Trends in Psychiatry and Psychotherapy
https://www.readbyqxmd.com/read/28481434/time-course-of-the-effects-of-lisdexamfetamine-dimesylate-in-two-phase-3-randomized-double-blind-placebo-controlled-trials-in-adults-with-binge-eating-disorder
#14
Susan L McElroy, James I Hudson, Maria Gasior, Barry K Herman, Jana Radewonuk, Denise Wilfley, Joan Busner
OBJECTIVE: This study examined the time course of efficacy-related endpoints for lisdexamfetamine dimesylate (LDX) versus placebo in adults with protocol-defined moderate to severe binge-eating disorder (BED). METHODS: In two 12-week, double-blind, placebo-controlled studies, adults meeting DSM-IV-TR BED criteria were randomized 1:1 to receive placebo or dose-optimized LDX (50 or 70 mg). Analyses across visits used mixed-effects models for repeated measures (binge eating days/week, binge eating episodes/week, Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE] scores, percentage body weight change) and chi-square tests (Clinical Global Impressions-Improvement [CGI-I; from the perspective of BED symptoms] scale dichotomized as improved or not improved)...
August 2017: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/28467032/comparative-effectiveness-of-treatments-for-binge-eating-disorder-systematic-review-and-network-meta-analysis
#15
REVIEW
Christine M Peat, Nancy D Berkman, Kathleen N Lohr, Kimberly A Brownley, Carla M Bann, Katherine Cullen, Mary J Quattlebaum, Cynthia M Bulik
Psychological and pharmacological interventions for binge-eating disorder have previously demonstrated efficacy (compared with placebo or waitlist control); thus, we aimed to expand that literature with a review of comparative effectiveness. We searched MEDLINE,® EMBASE,® Cochrane Library, Academic OneFile, CINAHL® for binge-eating disorder treatment articles and selected studies using predetermined inclusion and exclusion criteria. Data were sufficient for network meta-analysis comparing two pharmacological interventions; psychological interventions were analysed qualitatively...
September 2017: European Eating Disorders Review: the Journal of the Eating Disorders Association
https://www.readbyqxmd.com/read/28440070/chiral-analysis-of-amphetamines-in-hair-by-liquid-chromatography-tandem-mass-spectrometry-compliance-monitoring-of-attention-deficit-hyperactivity-disorder-adhd-patients-under-elvanse%C3%A2-therapy-and-identification-after-controlled-low-dose-application
#16
Tina M Binz, Elena Williner, Petra Strajhar, Patrick C Dolder, Matthias E Liechti, Markus R Baumgartner, Thomas Kraemer, Andrea E Steuer
Amphetamine (AMP) is used as illicit drug but also for the treatment of attention deficit hyperactivity disorder (ADHD). Respective drugs most often contain the enantiomer (S)-AMP as active compound or (S)-AMP is formed from the prodrug lisdexamfetamine (Elvanse®) whereas the illicit drug is usually traded as racemate ((R/S)-AMP). A differentiation between the use of the medically prescribed drug and the abuse of illicit street amphetamine is of great importance e.g. in retrospective consumption monitoring by hair analysis...
April 24, 2017: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28383364/a-phase-3-multicenter-open-label-12-month-extension-safety-and-tolerability-trial-of-lisdexamfetamine-dimesylate-in-adults-with-binge-eating-disorder
#17
MULTICENTER STUDY
Maria Gasior, James Hudson, Javier Quintero, M Celeste Ferreira-Cornwell, Jana Radewonuk, Susan L McElroy
BACKGROUND: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). METHODS: Adults (aged 18-55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label extension study (dose optimization, 4 weeks [initial titration dose, 30-mg LDX; target doses, 50- or 70-mg LDX]; dose maintenance, 48 weeks). Safety evaluations included the occurrence of treatment-emergent adverse events (TEAEs), vital sign and weight assessments, and Columbia-Suicide Severity Rating Scale responses...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28376679/dopamine-and-%C3%AE-opioid-receptor-dysregulation-in-the-brains-of-binge-eating-female-rats-possible-relevance-in-the-psychopathology-and-treatment-of-binge-eating-disorder
#18
David J Heal, Michelle Hallam, Michael Prow, Jane Gosden, Sharon Cheetham, Yong K Choi, Frank Tarazi, Peter Hutson
Adult, female rats given irregular, limited access to chocolate develop binge-eating behaviour with normal bodyweight and compulsive/perseverative and impulsive behaviours similar to those in binge-eating disorder. We investigated whether (a) dysregulated central nervous system dopaminergic and opioidergic systems are part of the psychopathology of binge-eating and (b) these neurotransmitter systems may mediate the actions of drugs ameliorating binge-eating disorder psychopathology. Binge-eating produced a 39% reduction of striatal D1 receptors with 22% and 23% reductions in medial and lateral caudate putamen and a 22% increase of striatal μ-opioid receptors...
June 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28372478/investigation-of-impulsivity-in-binge-eating-rats-in-a-delay-discounting-task-and-its-prevention-by-the-d-amphetamine-prodrug-lisdexamfetamine
#19
Steven P Vickers, Simon Goddard, Richard J Brammer, Peter H Hutson, David J Heal
Freely-fed, female, rats were trained in a two-lever, delay-discounting task: one lever delivered a single chocolate-flavoured pellet immediately and the other a three-pellet reward after increasing delay (0, 4, 8, 16, 32 s). Rats were divided into two groups (i.e. binge-eating rats given irregular, limited access to chocolate in addition to normal chow and controls maintained on normal chow). Both groups exhibited increased preference for the immediate reward as the delay interval was lengthened. The discounting rate was significantly greater in binge-eating rats than non-binge-eating controls, especially as the behaviour became more established indicating that increased impulsivity and intolerance of delayed reward are part of the psychopathology of binge-eating...
June 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28351466/adhd-in-germany-trends-in-diagnosis-and-pharmacotherapy
#20
Christian J Bachmann, Alexandra Philipsen, Falk Hoffmann
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) sometimes persists into adulthood. There have been no studies from Germany until the present time on the diagnosis and treatment of ADHD over the course of patients' lives, in particular during the transition from adolescence to early adulthood. METHODS: We used nationwide routine data of the AOK statutory healthinsurance fund to determine the frequency of ADHD diagnoses and prescriptions of medication for ADHD...
March 3, 2017: Deutsches Ärzteblatt International
keyword
keyword
7577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"